10/577973 IAP20 RSC' C FUTTIFFO 03 MAY 2005

ATTORNEY DOCKET NO. 50318/013001

Date of Deposit: May 3, 2006 Label Number: EV 919876156 US I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Elvis De La Cruz Printed name of person mailing correspondence Signature of person mailing correspondence	Certificate of Mailing		
"Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Elvis De La Cruz	Date of Deposit: May 3, 2006	Label Number: EV 919876156 US	
	Express Mail Post Office to Addressee with sufficient postage on the date indicated above and is addressed to Mail Stop		
Printed name of person mailing correspondence Signature of person mailing correspondence	Elvis De La Cruz	en loun Co	
	Printed name of person mailing correspondence	Signature of person mailing correspondence	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Ensoli et al.

Confirmation No.: Not yet assigned

Serial No.:

Not yet assigned

Art Unit:

Not yet assigned

Filed:

May 3, 2006

Examiner:

Not yet assigned

Customer No.:

21559

Title:

Nanoparticles for Delivery of a Pharmacologically Active Agent

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. § 1.821

As part of the patent application filed herewith, enclosed is a Sequence Listing in accordance with the requirements of 37 C.F.R. § 1.821 through § 1.824 and consisting of 23 pages.

As required by 37 C.F.R. § 1.821(c), the Sequence Listing appears as a separate part of the application. Each sequence in the application appears separately in the Sequence Listing, and each sequence in the Sequence Listing is assigned a separate sequence identifier.

£0/577973 4720113113113110 03 MAY 2006

As required by 37 C.F.R. § 1.821(d), the sequence identifiers are used throughout the application description and claims to refer to their respective sequences.

As required by 37 C.F.R. § 1.821(e), enclosed is a diskette containing a copy of the Sequence Listing in computer readable form.

As required by 37 C.F.R. § 1.821(f), I hereby state that the contents of the computer readable form of the Sequence Listing are the same as the contents of the paper copy.

As required by 37 C.F.R. § 1.821(g), I hereby state that this submission contains no new matter.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: May 3, 2006

Susan M. Michaud, Ph.D.

Reg. No. 42,885

Clark & Elbing LLP 101 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045